GLUCOKINASE ACTIVATORS Russian patent published in 2012 - IPC C07D417/12 C07D417/14 C07D498/04 C07D495/04 C07D487/04 C07D491/48 C07D471/04 C07D513/04 A61K31/4427 A61K31/497 A61P3/10 

FIELD: chemistry.

SUBSTANCE: invention relates to compounds of formula I , and pharmaceutically acceptable salts thereof, where L denotes O, S, or CH₂; Y denotes N or CH; Z denotes CR₃; G denotes CH; R¹ denotes a heteroaryl ring of formula , where D¹ denotes S, O; D² denotes N or CR¹²; D³ denotes CR¹²; R² denotes (C₆-C₁₀)-aryl; 5-9-member mono- or bicyclic heteroaryl with 1 or 2 heteroatoms independently selected from N or S; a saturated or partially saturated (C₃-C₇)-cycloalkyl; or a saturated 5-6-member heteocyclyl with 1 heteroatom selected from N, where said aryl, heteroaryl, cycloalkyl and heterocyclyl are optionally substituted with one or two groups independently selected from (C₁-C₆)-alkyl, F, Cl, Br, CF₃, CN, NO₂, OR⁶, C(-O)R⁶, C(=O)OR⁶, C(=O)NR⁶R⁷, saturated 6-member heterocyclyl with 2 heteroatoms independently selected from N or O, and S(O)₂R⁶, and where said alkyl is optionally substituted with one -OR⁸ group; R³ denotes H; (C₁-C₆)-alkyl; (C₂-C₆)-alkenyl; Cl; Br; OR⁶; SR⁶; phenyl; or a 6-member heteroaryl with 1 heteroatom selected from N, where said alkyl and alkenyl are optionally substituted with one group selected from C(=O)OR⁸, -OR⁸, -NR⁸R⁹; or a saturated 6-member heterocyclyl with 1 heteroatom selected from N or O.

EFFECT: disclosed compounds are used in treating and preventing diseases mediated by insufficient level of glucokinase activity, such as sugar diabetes.

16 cl, 479 ex